Commercial momentum Syndax is a commercial-stage biopharma with recent strong Q1 2026 revenue growth driven by launches of Revuforj and Niktimvo, indicating growing market adoption and a ripe window for strategic partnerships and co-promotion opportunities with oncology-focused distributors and providers.

Pipeline breadth A diversified pipeline including a menin inhibitor for relapsed/refractory acute leukemia and a CSF-1 receptor monoclonal antibody for chronic graft-versus-host disease presents multiple cross-therapy collaboration avenues, including academic partnerships, companion diagnostics, and combination therapy studies.

Clinical exposure Active and upcoming clinical trial programs and an upcoming R&D Day signal opportunities to engage KOLs, contract research organizations, and clinical researchers for trial support, site networks, and early-access discussions with healthcare systems.

Financial capacity With funding of approximately $1.4B and revenue in the multi‑hundred million range, Syndax has solid financial backing to pursue strategic collaborations, out-licensing, or co-development deals with pharma and biotech partners seeking late-stage or near-term assets.

Industry engagement Active investor relations presence and frequent industry events, including ASH, J.P. Morgan Healthcare Conference, Guggenheim biotech summit, and an upcoming R&D Day, provide plentiful touchpoints for partnerships, licensing discussions, and sponsorable patient access programs.